Clinical Trials Logo
  1. Home
  2. Cancer of Prostate
  3. NCT02614859

Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients — BIMET-1  

Cancer of Prostate Clinical Trial

Official title:
Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients (BIMET-1)

Clinical Trial Summary

Obesity and metabolic syndrome are prevalent among prostate cancer patients. Having an elevated insulin level in the blood is associated with a shorter median time to cancer progression and median overall survival in patients with an elevated PSA after prior treatment. Androgen deprivation therapy (ADT) with drugs like bicalutamide is frequently used in this patient population,with no proven benefit, which may increase mortality and morbidity.This study evaluates how metformin in combination with bicalutamide affects prostate cancer.

Clinical Trial Description

1 Cycle = 28 days = 4 weeks. Treatment will be administered on an outpatient basis ΣΏ Metformin starting dose is 500 mg BID, will be gradually increased to target dose of 1000mg BID. Treatment ARM A Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32). Treatment ARM B Cycles 1 - 2: In order to minimize gastrointestinal discomfort, metformin dosing will be ramped up over a period of 2 weeks. Metformin treatment will be started at 500 mg BID (Dose Level -2) and increased by an increment of 500 mg daily every week +/- 2 days provided no grade 2 or higher gastrointestinal toxicity is noted. If grade 2 or greater gastrointestinal toxicity occurs during the first 4 weeks of treatment, the subject will be evaluated every 2 weeks until resolution of toxicity to grade 0 or 1 and, then, the metformin dose will be increased to the next dose level. The target dose of metformin is 1000 mg BID. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02614859
Study type Interventional
Source Fox Chase Cancer Center
Contact
Status Completed
Phase Phase 2
Start date December 1, 2015
Completion date January 24, 2020
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT03031418 - Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
Completed NCT01639859 - Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci N/A
Not yet recruiting NCT06406803 - The Impact of Physical Activity Versus Dietary Energy Restriction on Tumour and Muscle Protein Synthesis in Prostate Cancer Patients N/A
Completed NCT02362464 - Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 Phase 2
Enrolling by invitation NCT05844761 - Real-time Motion Management During Prostate and Lung Radiotherapy N/A
Completed NCT03442075 - Pain Comparison Whit Visual Analog Scale (EVA) Between Four Analgesic Methods During Trans Rectal Prostatic Biopsy
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed NCT03444532 - Feasibility Study Testing a Sleep Intervention in Prostate Cancer Patients With Insomnia N/A
Recruiting NCT05600400 - Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer N/A
Recruiting NCT04887935 - Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer Phase 1
Completed NCT02235142 - Prostatic Cancer Versus Androgen Deficiency N/A
Recruiting NCT06318559 - Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention N/A
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2
Active, not recruiting NCT03632980 - Dynamic Focusing Evaluation for Prostate Cancer Treatment N/A
Recruiting NCT04319783 - Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA Phase 2
Recruiting NCT04258813 - Onco-primary Care Networking to Support TEAM-based Care N/A
Recruiting NCT05361798 - T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy Phase 2